Screener
Prestige Consumer Healthcare PBH Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Prestige Consumer Healthcare in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Prestige Consumer Healthcare’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 6:15 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001295947-26-000042
FAQ
- What is Prestige Consumer Healthcare's cash & equivalents?
- Prestige Consumer Healthcare (PBH) reported cash & equivalents of $89.13M in Q2 2026.
- How has Prestige Consumer Healthcare's cash & equivalents changed year-over-year?
- Prestige Consumer Healthcare's cash & equivalents decreased by 36.1% year-over-year, from $139.5M to $89.13M.
- What is the long-term trend for Prestige Consumer Healthcare's cash & equivalents?
- Over 5 years (2021 to 2026), Prestige Consumer Healthcare's cash & equivalents has grown at a 14.6% compound annual growth rate (CAGR), from $32.3M to $63.87M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Prestige Consumer Healthcare's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude